University of Miami Miller School of Medicine, Miami, FL, USA.
Ophthalmology. 2012 May;119(5):979-86. doi: 10.1016/j.ophtha.2011.11.003. Epub 2012 Feb 18.
Glaucoma is a progressive neurodegenerative disease of retinal ganglion cells (RGCs) associated with characteristic axon degeneration in the optic nerve. Clinically, our only method of slowing glaucomatous loss of vision is to reduce intraocular pressure (IOP), but lowering IOP is only partially effective and does not address the underlying susceptibility of RGCs to degeneration. We review the recent steps forward in our understanding of the pathophysiology of glaucoma and discuss how this understanding has given us a next generation of therapeutic targets by which to maintain RGC survival, protect or rebuild RGC connections in the retina and brain, and enhance RGC function.
青光眼是一种进行性的神经退行性疾病,与视神经中特征性的轴突变性有关。临床上,我们减缓青光眼视力丧失的唯一方法是降低眼内压(IOP),但降低 IOP 只是部分有效,不能解决 RGC 易变性的根本问题。我们回顾了近年来在青光眼病理生理学理解方面的进展,并讨论了这种理解如何为我们提供了新一代的治疗靶点,以维持 RGC 的存活,保护或重建视网膜和大脑中的 RGC 连接,并增强 RGC 的功能。